Transport of Glyburide by Placental ABC Transporters: Implications in Fetal Drug Exposure

Gedeon, C.; Behravan, Javad; Koren, Gideon; Piquette-Miller, Micheline

doi:10.1016/j.placenta.2005.11.012

Cited by 123 publications

(95 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, an extremely conservative posture due to fear of embryo/fetus toxicity, in some cases, might lead a woman to unnecessary suffering (Fonseca, Fonseca, Bergsten-Mendes, 2002). Furthermore, some maternal pathologic situations that often result in a high-risk pregnancy should be prioritized and pharmacologically treated, under commitment penalty of pregnancy and/or generate more risks to the mother and to the fetus (Gedeon et al, 2006).…”

Section: Resultsmentioning

confidence: 99%

Consumption of medicines in high-risk pregnancy: evaluation of determinants related to the use of prescription drugs and self-medication

Araújo

Leal

Santos

et al. 2013

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The use of drugs during pregnancy still represents a challenge for medicine, since the majority of drugs cross the placental barrier with a potential to cause several congenital problems to the fetus, and most of them have not been clinically tested in pregnant patients. At the same time, the medicalization phenomenon, self-medication, and lack of patient information about the misuse of medicines are additional problems. Thus, the aim of this study was to evaluate the pattern of medicine consumption in high-risk pregnancies and the determinants related to this consumption pattern. In order to do so, a cross-sectional descriptive study was performed with puerperal women who had a history of high-risk pregnancy. Statistically significant associations were found between self-medication and fewer prenatal visits, and cigarette use during pregnancy and a higher number of children. According to these data, the vulnerability of this population to the risks of drug use is evident, demonstrating a gap that requires urgent interventions in health-care education.Uniterms: Medicines/adverse effects. Pregnancy/medicines use. Self-medication. Health education.O uso de medicamentos na gestação representa, ainda hoje, um desafio para a medicina, visto que grande parte dos fármacos atravessa a barreira placentária e, na maioria, não foi testada clinicamente em gestantes, podendo vir a ocasionar diversos problemas congênitos ao feto. Ao mesmo tempo, a automedicação, o fenômeno da medicalização e a falta de informação sobre os riscos do mau uso de medicamentos são problemas adicionais. Diante disto, o objetivo deste estudo consistiu em avaliar o padrão de consumo de medicamentos na gestação de alto risco e os determinantes relacionados ao seu padrão de consumo. Para tanto, realizou-se um estudo descritivo de corte transversal com puérperas, que apresentaram gestação de alto risco. Verificaram-se associações estatisticamente significativas entre automedicação e mulheres com menor número de consultas de pré-natal, uso de cigarro na gestação e maior número de filhos. De posse destes dados, fica evidente a vulnerabilidade dessa população aos riscos decorrentes do uso de medicamentos, sendo esta lacuna um campo de prática com necessidade de intervenções urgentes no âmbito da educação em saúde.Unitermos: Medicamentos/efeitos adversos. Gestação/uso de medicametos. Automedicação. Educação em saúde.

show abstract

Section: Resultsmentioning

confidence: 99%

Consumption of medicines in high-risk pregnancy: evaluation of determinants related to the use of prescription drugs and self-medication

Araújo

Leal

Santos

et al. 2013

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…Chenodeoxycholate-3-sulfate [15] 131 Glycodeoxycholate [15] 2.0 Glycoursodeoxycholate [15] 4.1 Cholate [15,54] [15,54] 7.3/13 Deoxycholate [15,54] 5.2-13 Glycochenodeoxycholate [54] 2.0/2.9 Glychodeoxycholate [54] 2.4/5.4 Glycholate [54] 11/21 Taurochenodeoxycholate [15,54] 1.0-6.1 Taurocholate [15,54] 7.3-25 Taurodeoxycholate [15] 4.5-17 Taurourosdeoxycholate [15] 28 Ursodeoxycholate [15,54] 36 [60] Estrone [56] Bisantrene [67] Betamethasone [57] Riboflavin [68] Taurolithocholate sulfate [56] 37 a Cerivastatin [61] Cerivastain [61] 18 Uric acid [69] Vitamin K3 [ [70] Ciprofloxacin [71] Daunorubicin [56] 59 a Daunorubicin [67] Dexamethasone [57] Diclofenac [72] Diclofenac [72] 71-78 Dipyridamole [73] Digoxin [57] Doxorubicin [67,74] Dipyridamole [73] 6.4 a Enrofloxacin [75] Doxorubicin [56,76] Epirubicin [67] Fluvastatin [61] 5.4 Fluvastatin [61,62] Glibenclamide [77] 150 a Glibenclamide …”

Section: Substrates and Inhibitorsmentioning

confidence: 99%

“…p-Aminohippuric acid [92] 372 Bilirubin biglucuronide [93] 0.8 a Daunorubicin [94,95] 1.4 Atazanavir [59] Bilirubin bisglucuronide [93] Bilirubin monoglucuronide [93] 0.4 a Grepafloxacin [96] Benzbromarone [97,98] Bilirubin monoglucuronide [93] E217bG [99] 22 Irinotecan [100] Benzylpenicillin [98] DHEAS [101] 5 Estradiol sulfate [102] 0.4 Methotrexate [98,103,104] 930/2150 Daunorubicin [99]~8a DNP-GS [105] 3.6 E23SO417bG [99] 1.7 Doxorubicin [99]~5 0 a E217bG [99,[105][106][107] 1.5-4.8 E316bG [99] 45 Mitoxantrone [108] Flurbiprofen [109] Estrone-3-sulfate [102] 0.7/4.2 E317bG [99] 1.4 Saquinavir [110] Furosemide [98] Folic acid [103] Estrone-3-sulfate [102] 0.5 Vinblastine [111] Glibenclamide [77] Glutathione [97,112] Glycholate [99] Vincristine [95,113] Indinavir [114] Leucovorin [103] Glycolithocholate-3-sulfate [99] 1.4 Indometacin …”

Section: Substrates and Inhibitorsmentioning

confidence: 99%

Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug–drug interactions

Grandvuinet

Vestergaard

Rapin³

et al. 2012

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives This review provides an overview of intestinal human transporters for organic anions and stresses the need for standardization of the various in‐vitro methods presently employed in drug–drug interaction (DDI) investigations. Key findings Current knowledge on the intestinal expression of the apical sodium‐dependent bile acid transporter (ASBT), the breast cancer resistance protein (BCRP), the monocarboxylate transporters (MCT) 1, MCT3‐5, the multidrug resistance associated proteins (MRP) 1–6, the organic anion transporting polypetides (OATP) 2B1, 1A2, 3A1 and 4A1, and the organic solute transporter α/β (OSTα/β) has been covered along with an overview of their substrates and inhibitors. Furthermore, the many challenges in predicting clinically relevant DDIs from in‐vitro studies have been discussed with focus on intestinal transporters and the various methods for deducting in‐vitro parameters for transporters (Km/Ki/IC50, efflux ratio). The applicability of using a cut‐off value (estimated based on the intestinal drug concentration divided by the Ki or IC50) has also been considered. Summary A re‐evaluation of the current approaches for the prediction of DDIs is necessary when considering the involvement of other transporters than P‐glycoprotein. Moreover, the interplay between various processes that a drug is subject to in‐vivo such as translocation by several transporters and dissolution should be considered.

show abstract

“…Thus, it is likely that ABC efflux transporters in the placenta play an important role in limiting fetal exposure to glyburide. To test this hypothesis, Gedeon et al examined the role of P-gp, BCRP and MRPs in the efflux of glyburide using stable cell lines expressing these transporters in the presence or absence of selective inhibitors (Gedeon et al, 2006). Their results suggested that glyburide was preferentially transported by BCRP and MRP3, but not by P-gp, MRP1 or MRP2.…”

Section: In Vivo Animal Studiesmentioning

confidence: 99%

Glyburide Disposition During Pregnancy

Shuster¹,

Hébert²,

Mao³

2011

Gestational Diabetes

View full text Add to dashboard Cite

Transport of Glyburide by Placental ABC Transporters: Implications in Fetal Drug Exposure

Cited by 123 publications

References 23 publications

Consumption of medicines in high-risk pregnancy: evaluation of determinants related to the use of prescription drugs and self-medication

Consumption of medicines in high-risk pregnancy: evaluation of determinants related to the use of prescription drugs and self-medication

Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug–drug interactions

Glyburide Disposition During Pregnancy

Contact Info

Product

Resources

About